Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1491-1500

  Visonneau, Sophie ^a   Cesano, Alessandra ^a   Torosian, Michael H ^b   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER REGRESSION; CASE REPORT; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELLS, CULTURED; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, SUBCUTANEOUS; LYMPHATIC METASTASIS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030873592     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 71-85, 1992.
2. Goldhirsch, A., Gelber, R. D., Price, K. N., Castiglione, M., Coates, A. S., Rudenstam, C. M., Collins, J., Lindtner, J., Hacking, A., Marini, G., Byrne, M., Cortés-Funes, H., SchnŸrch, G., Brunner, K. W., Tattersall, M. H. N., Forbes, J., and Senn, H. J. Effect of systemic treatment on first sites of breast cancer relapse. Lancet, 343: 370-371 1994.
3. Lippmann, M. E. The development of biological therapies for breast cancer. Science (Washington DC), 259: 631-632, 1993.
4. O'Connor, R., Cesano, A., Lange, B., Finan, J., Nowell, P. C., Clark, S. C., Raimondi, S. C., Rovera, G., and Santoli, D. Growth factor requirements of childhood acute T lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood, 77: 1534-1545, 1991.
5. Cesano, A., and Santoli, D. Two unique leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity: analysis and modulation of their lytic mechanisms. In Vitro Cell. & Dev. Biol., 28A: 648-656, 1992.
6. Cesano, A., and Santoli, D. Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell. & Dev. Biol., 28A: 657-662, 1992.
7. Cesano, A., Visonneau, S., Clark, S. C., and Santoli, D. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol., 151: 2943-2957, 1993.
8. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., Rovera, G., and Santoli, D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest., 94: 1076-1084, 1994.
9. Cesano, A., Visonneau, S., and Santoli, D. Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T cell line. Cancer Res., 55: 96-101, 1995.
10. Cesano, A., Visonneau, S., Jeglum, K. A., Owen, J., Wilkinson, K., Carner, K., Reese, L., and Santoli, D. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res., 56: 3021-3029, 1996.
11. Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., and Santoli, D. Antitumor efficacy of a human MHC non-restricted cytotoxic T cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res., 56: 4444-4452, 1996.
12. Whittington, R., and Faulds, D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer Drugs, 46: 446-513, 1993.
13. Rosenberg, S. A., Packard, B. S., Aebersold, P. N., Solomon, D., Topalian, S. L., Toy, S. T., Simon, R., Lotze, M. T., Yang, J., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E. Use of tumor infiltrating lymphocytes and interleukin-2 in immunotherapy of patients with metastatic melanoma N. Engl. J. Med., 319: 1676-1680, 1988.
14. Bartek, J., Vojtesek, B., Staskova, Z., Bartkova, J., Kerekes, Z., Rejthar, A., and Kovarik, J. A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology J. Pathol., 164: 215-224, 1991.
15. Mackinnon, S., Barnett, L., Bourhis, J. H., Black, P., Heller, G., and O'Reilly, R. J. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood, 80: 3235-3241, 1992.
16. Lee, M. Y. T. Patterns of metastasis and natural course of breast carcinoma. Cancer Metastasis Rev., 4: 153-157, 1985.
17. Price, J. E. The biology of metastatic breast cancer. Cancer (Phila.), 66: 1313-1320, 1990.
18. Price, J., and Zhang, R. D. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev., 8: 285-297, 1990.
19. Brunner, N., Osborne, C. K., and Spang-Thomsen, M. Endocrinotherapy of human breast cancer growth in nude mice. Breast Cancer Res. Treat., 10: 229-242, 1987.
20. Mueller, B., and Reisfeld, R. A. Potential of the SCID mouse as a host for human tumors. Cancer Metastasis Rev., 10: 193-200, 1991.
21. Phillips, R. A., Jewett, M. A., and Gallie, B. L. Growth of human tumors in immune-deficient SCID mice and nude mice. Curr. Top. Microbiol. Immunol., 152: 259-263, 1989.
22. Sakakibara, T., Xu, Y., Bumpers, H. L., Chen, F-A., Bankert, R. B., Arredondo, M. A., Edge, S. B., and Repasky, E. A. Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J. Sci. Am., 2: 291-300, 1996.
23. Cesano, A., Hoxie, J. A., Lange, B., Nowell, P. C., Bishop, J., and Santoli, D. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 7: 827-836, 1992.
24. Cesano, A., and Santoli, D. The SCID mouse as a model for human leukemias. In: R. Namikawa and M. G. Roncarolo (eds.), Human Hematopoiesis in SCID Mice, pp. 171-196. Austin, TX: R. G. Landes Publishing Company Medical Intelligence Unit, 1995.
25. Jakubowski, A. Myelosuppression. In: J. M. Kirkwood, M. T. Lotze, and J. M. Yasko (eds.), Current Cancer Therapeutics, Ed. 2, pp. 317-322. Philadelphia: Churchill-Livingstone, 1996.
26. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., and Santoli, D. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy. Cancer Immunol. Immunother., 40: 139-151, 1995.
27. Cesano, A., O'Connor, R., Lange, B., Finan, J., Rovera, G., and Santoli, D. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood, 77: 2463-2474, 1991.